Abstract
In the present study we investigated in vivo therapeutic potential of DCs vaccines in B-cell chronic lymphocytic leukemia (B-CLL). On the day 0 the SCID mice were intraperitoneally inoculated with peripheral blood mononuclear cells (PBMC) of B-CLL patients at a dose of 10-30 × 106 and left untreated (controls) or i.p. injected on the day 7 with 0.2-14.0 × 106 dendritic cells. DCs were generated in vitro from peripheral blood monocytes of B-CLL donors (autologous DCs) or healthy donors (allogeneic cells) and pulsed with B-CLL antigens. On the day 14, the effect of implanted cells interactions was evaluated by a counting of CD19+CD5+ human leukemic cells and human T cells in the peritoneal fluid of mice. We found, that mean numbers of CD19+CD5+ leukemic cells as well as human T cells were lowered in peritoneal fluid of mice treated with allogeneic APCs. However, we did not observe similar effects with autologous DCs. © Polish Histochemical et Cytochemical Society.
Author supplied keywords
Cite
CITATION STYLE
Hus, I., Kawiak, J., Hoser, G., Tabarkiewicz, J., Radej, S., Dmoszynska, A., & Rolinski, J. (2009). SCID mice model in vivo evaluation of autologous and allogeneic dendritic cells activity on B-cell chronic lymphocytic leukemia. Folia Histochemica et Cytobiologica, 47(4), 563–570. https://doi.org/10.2478/v10042-008-0101-9
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.